ProQR Therapeutics N.V. (NASDAQ:PRQR) – Investment analysts at Leerink Swann upped their Q3 2017 EPS estimates for ProQR Therapeutics N.V. in a research report issued to clients and investors on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($0.49) per share for the quarter, up from their previous forecast of ($0.53). Leerink Swann also issued estimates for ProQR Therapeutics N.V.’s Q4 2017 earnings at ($0.51) EPS, FY2017 earnings at ($2.08) EPS, FY2018 earnings at ($1.44) EPS and FY2019 earnings at ($1.68) EPS.

Several other equities research analysts also recently commented on the company. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of ProQR Therapeutics N.V. in a report on Tuesday, June 20th. Zacks Investment Research upgraded ProQR Therapeutics N.V. from a “sell” rating to a “hold” rating in a report on Wednesday, May 3rd. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $14.05.

ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/18/brokers-offer-predictions-for-proqr-therapeutics-n-v-s-q3-2017-earnings-prqr.html.

ProQR Therapeutics N.V. (PRQR) opened at 4.35 on Friday. The stock’s 50 day moving average is $5.12 and its 200 day moving average is $4.81. ProQR Therapeutics N.V. has a 52 week low of $3.65 and a 52 week high of $8.70. The company’s market capitalization is $104.36 million.

ProQR Therapeutics N.V. (NASDAQ:PRQR) last issued its quarterly earnings results on Wednesday, May 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.02.

Large investors have recently made changes to their positions in the company. Hikari Power Ltd bought a new stake in shares of ProQR Therapeutics N.V. during the first quarter valued at about $121,000. Sphera Funds Management LTD. increased its stake in shares of ProQR Therapeutics N.V. by 65.0% in the first quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock valued at $1,650,000 after buying an additional 130,000 shares during the period. Artal Group S.A. increased its stake in shares of ProQR Therapeutics N.V. by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after buying an additional 100,000 shares during the period. Janus Henderson Group PLC bought a new stake in shares of ProQR Therapeutics N.V. during the second quarter valued at about $2,028,000. Finally, Redmile Group LLC increased its stake in shares of ProQR Therapeutics N.V. by 2.8% in the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after buying an additional 43,050 shares during the period. Institutional investors and hedge funds own 35.70% of the company’s stock.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.